Renee-Claude Mercier, PharmD

Gilead Sciences, Inc.

Poster(s):

• P3779 - Final Results of MYR301: A Randomized Phase 3 Study Evaluating the Efficacy and Safety of Up to 144 Weeks of Bulevirtide Monotherapy for Chronic Hepatitis Delta and 96 Weeks of Post-Treatment Follow-Up
  Monday, October 27, 2025

  10:30 AM - 4:00 PM PDT

• P3780 - Achieving Undetectable Hepatitis Delta Virus RNA at End of Therapy With Bulevirtide 10 Mg/day With or Without PegIFNα Is Strongly Associated With Posttreatment Virologic Response in Chronic Hepatitis Delta
  Monday, October 27, 2025

  10:30 AM - 4:00 PM PDT

• P3781 - Predictors of Undetectable Hepatitis Delta Virus RNA at 48 Weeks After End of Treatment With Bulevirtide Monotherapy in the MYR 301 Study
  Monday, October 27, 2025

  10:30 AM - 4:00 PM PDT